{"success":true,"data":{"pressRelease":{"id":"80198","rtpr_id":"nACSWh6cXa","ticker":"GRAL","exchange":"NASDAQ","all_tickers":["GRAL"],"title":"GRAL Court Reminder: GRAIL, Inc. Investors are Notified to Act before the Upcoming Securities Fraud Class Action Deadline on August 4","author":"ACCESSWIRE","published_at":"2026-07-03T19:18:01.416Z","article_body":"A securities fraud class action lawsuit has been filed on behalf of GRAIL\ninvestors after its stock plummeted 50% because GRAIL allegedly misled\ninvestors relating to GRAIL's NHS-Galleri cancer trial, potentially violating\nfederal securities laws.\n\nNEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n3, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/na1e) announces that a class action lawsuit has been filed\nagainst GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in GRAIL, you are encouraged to obtain additional information\nby visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit.\n\nKey Details of the GRAIL ($GRAL) Class Action:\n*\nLead Plaintiff Deadline: August 4, 2026\n*\nAlleged Misconduct: Securities fraud relating to GRAIL's NHS-Galleri cancer\ntrial\n*\nStock Drop: February 20, 2026 - 50.55% Stock Drop\n*\nCourt: U.S. District Court for the Northern District of California\n*\nAction: Contact BFA Law (https://pr.report/na1g) to discuss your rights\n\nInvestors have until August 4, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nGRAIL common stock. The class action is pending in the U.S. District Court for\nthe Northern District of California. It is captioned Robbins v. GRAIL, Inc.,\net al., No. 26-cv-05428.\n\nWhy is GRAIL Being Sued for Securities Fraud?\n\nGRAIL is a commercial-stage healthcare company focused on early cancer\ndetection. GRAIL developed Galleri, a multi-cancer early detection test that\nanalyzes blood samples to screen for multiple cancers, identify the likely\norgan or tissue of origin, and assist in the screening process. As part of\nGRAIL's efforts to attain an accelerated implementation of its test as a\nnational screening program through the United Kingdom's National Health\nService (\"NHS\"), GRAIL conducted the \"NHS-Galleri trial.\" The primary\nobjective of the NHS-Galleri trial was \"to show a reduction in late-stage\n(III-IV) cancers in people who received the Galleri test compared with those\nwho did not.\"\n\nAccording to the complaint, during the relevant period, GRAIL made positive\nstatements about Galleri, the NHS-Galleri trial design, and top-line results\nfrom the first screening round, including that the NHS-Galleri trial was\n\"designed with three consecutive years of screening in order to achieve the\nprimary endpoint,\" and that \"Galleri is working in the real world.\"\n\nAs alleged, in truth, the NHS-Galleri trial's three-year timeframe was\ninsufficient to demonstrate the primary endpoint.\n\nWhy did GRAIL's Stock Drop?\n\nOn February 19, 2026, GRAIL announced top-line results from its NHS-Galleri\ntrial. Although the Company emphasized certain favorable results, GRAIL\ndisclosed that the trial did not meet its primary endpoint. Specifically,\nGRAIL stated that the \"primary endpoint of statistically significant Stage\nIII-IV reduction was not observed.\" GRAIL attributed the disappointing\noutcome, in part, to \"probably need[ing] a longer follow-up time to be able to\n[compare the two arms of the study] adequately.\"\n\nThis news caused the price of GRAIL stock to decline $51.32 per share, or\n50.55%, from a closing price of $101.53 per share on February 19, 2026, to\n$50.21 per share on February 20, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/grail-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in GRAIL, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/grail-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/grail-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar, Fonti, & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/gral-court-reminder-grail-inc.-investors-are-notified-to-act-bef-1185458)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSWh6cXa","title":"GRAL Court Reminder: GRAIL, Inc. Investors are Notified to Act before the Upcoming Securities Fraud Class Action Deadline on August 4","author":"ACCESSWIRE","ticker":"GRAL","created":"2026-07-03T19:18:01.416Z","tickers":["GRAL"],"exchange":"NASDAQ","article_body":"A securities fraud class action lawsuit has been filed on behalf of GRAIL\ninvestors after its stock plummeted 50% because GRAIL allegedly misled\ninvestors relating to GRAIL's NHS-Galleri cancer trial, potentially violating\nfederal securities laws.\n\nNEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n3, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/na1e) announces that a class action lawsuit has been filed\nagainst GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in GRAIL, you are encouraged to obtain additional information\nby visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit.\n\nKey Details of the GRAIL ($GRAL) Class Action:\n*\nLead Plaintiff Deadline: August 4, 2026\n*\nAlleged Misconduct: Securities fraud relating to GRAIL's NHS-Galleri cancer\ntrial\n*\nStock Drop: February 20, 2026 - 50.55% Stock Drop\n*\nCourt: U.S. District Court for the Northern District of California\n*\nAction: Contact BFA Law (https://pr.report/na1g) to discuss your rights\n\nInvestors have until August 4, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nGRAIL common stock. The class action is pending in the U.S. District Court for\nthe Northern District of California. It is captioned Robbins v. GRAIL, Inc.,\net al., No. 26-cv-05428.\n\nWhy is GRAIL Being Sued for Securities Fraud?\n\nGRAIL is a commercial-stage healthcare company focused on early cancer\ndetection. GRAIL developed Galleri, a multi-cancer early detection test that\nanalyzes blood samples to screen for multiple cancers, identify the likely\norgan or tissue of origin, and assist in the screening process. As part of\nGRAIL's efforts to attain an accelerated implementation of its test as a\nnational screening program through the United Kingdom's National Health\nService (\"NHS\"), GRAIL conducted the \"NHS-Galleri trial.\" The primary\nobjective of the NHS-Galleri trial was \"to show a reduction in late-stage\n(III-IV) cancers in people who received the Galleri test compared with those\nwho did not.\"\n\nAccording to the complaint, during the relevant period, GRAIL made positive\nstatements about Galleri, the NHS-Galleri trial design, and top-line results\nfrom the first screening round, including that the NHS-Galleri trial was\n\"designed with three consecutive years of screening in order to achieve the\nprimary endpoint,\" and that \"Galleri is working in the real world.\"\n\nAs alleged, in truth, the NHS-Galleri trial's three-year timeframe was\ninsufficient to demonstrate the primary endpoint.\n\nWhy did GRAIL's Stock Drop?\n\nOn February 19, 2026, GRAIL announced top-line results from its NHS-Galleri\ntrial. Although the Company emphasized certain favorable results, GRAIL\ndisclosed that the trial did not meet its primary endpoint. Specifically,\nGRAIL stated that the \"primary endpoint of statistically significant Stage\nIII-IV reduction was not observed.\" GRAIL attributed the disappointing\noutcome, in part, to \"probably need[ing] a longer follow-up time to be able to\n[compare the two arms of the study] adequately.\"\n\nThis news caused the price of GRAIL stock to decline $51.32 per share, or\n50.55%, from a closing price of $101.53 per share on February 19, 2026, to\n$50.21 per share on February 20, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/grail-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in GRAIL, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/grail-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/grail-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar, Fonti, & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/gral-court-reminder-grail-inc.-investors-are-notified-to-act-bef-1185458)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-07-03T19:18:01.533362393Z","server_sent_at_ms":1783106281533},"received_at":"2026-07-03T19:18:01.598Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/gral-court-reminder-grail-inc.-investors-are-notified-to-act-bef-1185458"},"analysis":{"id":"69435","press_release_id":"80198","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP issued a reminder to GRAIL, Inc. investors regarding the upcoming lead plaintiff deadline in a securities fraud class action lawsuit.\n\nThe suit alleges GRAIL misled investors concerning its NHS-Galleri cancer trial, which reportedly failed to meet its primary endpoint and triggered a significant stock decline in February 2026.\n\nThis is a third-party solicitation for shareholders to seek lead plaintiff status before the August 4, 2026 deadline and contains no new disclosure from the company.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[],"products":[],"companies":[{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"target"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"GRAL"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"established-healthcare-name","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP issued a reminder to GRAIL, Inc. investors regarding the upcoming lead plaintiff deadline in a securities fraud class action lawsuit.\n\nThe suit alleges GRAIL misled investors concerning its NHS-Galleri cancer trial, which reportedly failed to meet its primary endpoint and triggered a significant stock decline in February 2026.\n\nThis is a third-party solicitation for shareholders to seek lead plaintiff status before the August 4, 2026 deadline and contains no new disclosure from the company.","key_figures":{},"named_entities":{"people":[],"products":[],"companies":[{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"target"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-06T03:44:10.102Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"established-healthcare-name","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":129028,"modelName":"george-droid-qwen-72b"}}